孟鲁司特治疗支气管哮喘的临床效果及对患者肺功能,Th1、Treg平衡的调节作用  

Clinical effect of montelukast in the treatment of bronchial asthma and its regulating effect on pulmonary function,Th1 and Treg balance in patients

作　　者：段胜利 DUAN Sheng-li(Special Inspection Department,Weifang Second People's Hospital,Weifang 261041,China)

机构地区：[1]潍坊市第二人民医院特检科,261041

出　　处：《中国实用医药》2022年第22期119-121,共3页China Practical Medicine

摘　　要：目的研究支气管哮喘临床治疗中应用孟鲁司特对患者肺功能,辅助性T细胞1(Th1)、调节性T细胞(Treg)平衡的调节作用及治疗效果。方法96例支气管哮喘患者为研究对象,按照数字随机法分成参照组及研究组,每组48例。参照组患者开展常规治疗,研究组在常规治疗的基础上应用孟鲁司特治疗。比较两组治疗效果,治疗前后的肺功能指标[第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)]水平,治疗前后Th1、Treg相关细胞因子[干扰素-γ(IFN-γ)、白细胞介素-10(IL-10)、IFN-γ/IL-10]水平。结果研究组治疗总有效率为93.75%,高于参照组的72.92%,差异具有统计学意义(P<0.05)。研究组患者治疗1、3个月时的FEV1分别为(1.31±0.03)、(1.45±0.27)L,FEV1/FVC分别为(56.90±5.27)%、(60.92±6.75)%,均高于参照组的(1.24±0.07)、(1.29±0.14)L和(54.01±5.09)%、(54.13±5.04)%,差异具有统计学意义(P<0.05)。治疗后,研究组IFN-γ(4.00±0.19)ng/L低于参照组的(4.36±0.48)ng/L,IL-10(3.06±0.55)ng/L、IFN-γ/IL-10(0.76±0.09)高于参照组的(2.00±0.63)ng/L、(0.46±0.05),差异具有统计学意义(P<0.05)。结论支气管哮喘患者应用孟鲁司特治疗,可以有效提高患者的肺功能,调节Th1、Treg的细胞平衡。Objective To study the clinical effect of montelukast in the treatment of bronchial asthma and its regulating effect on pulmonary function,helper T cells 1(Th1),regulatory T cells(Treg)balance in patients.Methods A total of 96 patients with bronchial asthma were selected as the research subjects,and were divided into reference group and research group according to random numerical table,with 48 cases in each group.Patients in the reference group treated with conventional therapy,and patients in the research group were treated with montelukast on the basis of conventional treatment.Both groups were compared in terms of therapeutic effect,pulmonary function indicators[forced expiratory volume in the 1st second(FEV1),FEV1/forced vital capacity(FVC)]levels,Th1,Treg-related cytokines[interferon-γ(IFN-γ),interleukin-10(IL-10),IFN-γ/IL-10]levels before and after treatment.Results The total effective rate of treatment in the research group was 93.75%,which was higher than 72.92%in the reference group,and the difference was statistically significant(P<0.05).The FEV1 of the research group at 1 and 3 months of treatment were(1.31±0.03),(1.45±0.27)L,and the FEV1/FVC were(56.90±5.27)%and(60.92±6.75)%,which were higher than(1.24±0.07),(1.29±0.14)L and(54.01±5.09)%,(54.13±5.04)%of the reference group,and the differences were all statistically significant(P<0.05).After treatment,the IFN-γ(4.00±0.19)ng/L in the research group was lower than(4.36±0.48)ng/L in the reference group,and the IL-10(3.06±0.55)ng/L,IFN-γ/IL-10(0.76±0.09)were higher than(2.00±0.63)ng/L,(0.46±0.05)in the reference group.The differences were all statistically significant(P<0.05).Conclusion The treatment of bronchial asthma patients with montelukast can effectively improve their pulmonary function and regulate the cellular balance of Th1 and Treg.

关 键 词：支气管哮喘 孟鲁司特 肺功能 辅助性T细胞1/调节性T细胞 

分 类 号：R562.25[医药卫生—呼吸系统]